Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 640-645

  McGuire, W ^a   Neugut, A I ^a   Arikian, S ^a   Doyle, J ^a   Dezii, C M ^a  

^a Ctr for Hlth Outcomes and Econ   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CEFTAZIDIME; CIPROFLOXACIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PARACETAMOL; VANCOMYCIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0031019914     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.640     Document Type: Article

References (9)

1. Yancik R: Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71:517-523, 1993 (suppl 2)
2. Thigpen JT, Blessing JA, Ball H, et al.: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
3. Williams CJ, Mead GM, Macbeth FR, et al.: Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: Mature results of a randomized trial. J Clin Oncol 3:1455-1462, 1985
4. Sutton GP, Stehman FB, Einhorn HL, et al.: Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223-229, 1989
5. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
6. Smith TJ, Hillner BE, Neighbors DM, et al.: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 13:2166-2173, 1995
7. Medicare Resource-Based Relative Value Schedule (RBRVS): The Physician Guide. Chicago, IL, American Medical Association, 1996
8. Oncology Drug and Supply Sourcebook: For the Community-Based Oncology Practice. San Francisco, CA, Oncology Therapeutics Network (OTN), Spring 1996
9. Kassirer JP, Angell M: The journals' policy on cost-effective analysis. N Engl J Med 331:669-670, 1994